About biofrontera inc. - BFRI
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company focuses on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.
BFRI At a Glance
Biofrontera, Inc.
120 Presidnetial Way
Woburn, Massachusetts 01801
| Phone | 1-781-245-1325 | Revenue | 41.71M | |
| Industry | Pharmaceuticals: Major | Net Income | -10,536,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 11.747% | |
| Fiscal Year-end | 12 / 2026 | Employees | 92 | |
| View SEC Filings |
BFRI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.139 |
| Price to Book Ratio | 0.634 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.671 |
| Enterprise Value to Sales | 0.133 |
| Total Debt to Enterprise Value | 1.108 |
BFRI Efficiency
| Revenue/Employee | 453,315.217 |
| Income Per Employee | -114,521.739 |
| Receivables Turnover | 4.901 |
| Total Asset Turnover | 1.646 |
BFRI Liquidity
| Current Ratio | 1.52 |
| Quick Ratio | 1.40 |
| Cash Ratio | 0.538 |
BFRI Profitability
| Gross Margin | 78.655 |
| Operating Margin | -21.935 |
| Pretax Margin | -25.203 |
| Net Margin | -25.263 |
| Return on Assets | -41.591 |
| Return on Equity | -141.30 |
| Return on Total Capital | -63.314 |
| Return on Invested Capital | -83.899 |
BFRI Capital Structure
| Total Debt to Total Equity | 58.788 |
| Total Debt to Total Capital | 37.023 |
| Total Debt to Total Assets | 21.569 |
| Long-Term Debt to Equity | 55.62 |
| Long-Term Debt to Total Capital | 35.028 |